The brief

Analyst view

• AlphaDBS won its CE mark in March 2025; a new release linked to the WebBioBank cloud got CE mark in July 2026.
• First patient implanted in the ADVENT pivotal trial on 21 September 2026 in Monza, Italy.
• ADVENT (104 patients, up to 18 US and EU sites) runs under an FDA IDE and is meant to support US approval.

Technical approach

As reported

Closed loop

Stimulation that follows the brain's state

Conventional DBS pulses at fixed settings all day; αDBS senses local brain signals and keeps stimulation inside a patient-specific window.

Data

Neural recordings sent to the cloud

A patient remote collects data at home and sends it to WebBioBank, a de-identified platform used for research and algorithm development.